|Bid||20.75 x 0|
|Ask||20.78 x 0|
|Day's Range||20.51 - 20.86|
|52 Week Range||6.73 - 21.30|
|Beta (5Y Monthly)||1.74|
|PE Ratio (TTM)||111.61|
|Earnings Date||Mar. 01, 2021 - Mar. 05, 2021|
|Forward Dividend & Yield||0.56 (2.67%)|
|Ex-Dividend Date||Sep. 14, 2020|
|1y Target Est||27.60|
Patients aged 70 or younger with previously untreated CLL lived longer without disease progression compared to patients treated with FCR, a chemoimmunotherapy regimenTORONTO, Jan. 13, 2021 /CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved IMBRUVICA® (ibrutinib) in combination with rituximab for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).
Here’s why value investors bullish on a recovery in the latter half of 2021 have a quality pick in Tourmaline Oil (TSX:TOU).The post Buy This 1 High-Quality Value Stock for a 2021 Recovery appeared first on The Motley Fool Canada.
This article will reflect on the compensation paid to Mike Rose who has served as CEO of Tourmaline Oil Corp. ( TSE:TOU...